Verve Therapeutics
@VerveTx
Cholesterol is more than just a number! It plays a major role in heart health. Keeping LDL (bad) and HLD (good) cholesterol levels in check is key to reducing your risk of heart disease and stroke. Watch the video from @American_Heart to learn more: youtube.com/watch?v=UaolDz…
On #ClinicalTrialsDay, we honor the people who power our purpose: the participants, investigators, and teams behind every trial. Every individual who takes part in a clinical trial plays a vital role in advancing science, accelerating innovation, and helping pave the way for a…
Verve is dedicated to developing transformative #geneediting medicines. We were thrilled to be selected once again to design cover art for @ACSPublications. The latest issue of Analytical Chemistry features our latest publication on how top-down mass spectrometry combined with…
The PCSK9 gene is a key regulator of cholesterol in the liver. At Verve, we are developing VERVE-102, a single-course #geneediting medicine, designed to permanently turn off the PCSK9 gene in the liver to reduce blood LDL-C, (also known as the “bad cholesterol”) levels in people…
We announced today that Verve has entered into a definitive agreement to be acquired by Eli Lilly and Company. Lilly shares our determination and dedication to transform the treatment paradigm for the millions of patients worldwide living with cardiovascular disease, and we…
At Verve, collaboration is more than a buzzword — it’s how breakthroughs begin. Whether we’re in the lab, in meetings, or sharing a coffee break, we believe that diverse voices and open minds drive bold science.
Members of the Verve leadership team will be participating in two upcoming healthcare investor conferences. We’re looking forward to connecting with the investment community to share updates on our progress and our mission to transform the treatment of #cardiovascular disease…
As part of the STEM Day at Fenway event, a few lucky Vervians spent the afternoon with students at the ballpark exploring the world of science through interactive demonstrations and hands-on activities. We love partnering with @SciScientists to inspire the next generation of…
Heading to the #TIDESUSA 2025 Oligonucleotide & Peptide Therapeutics conference in San Diego? Don’t miss our Chief Scientific Officer Troy Lister’s, Ph.D. presentation discussing how Verve utilizes #geneediting to potentially lower cholesterol to treat #cardiovascular disease on…
Our co-founder and CEO @skathire will be presenting at the RBC Capital Markets Global Healthcare Conference in New York next week. Join us on Wednesday, May 21 as we discuss our mission to transform the treatment of #cardiovascular disease through single-course gene editing…
Today, we reported pipeline updates and financial results for Q1 2025. Read the full announcement, as well as an overview of our programs here: ir.vervetx.com/news-releases/…
One question we ask ourselves is: Can we develop a single-course #baseediting treatment that mimics natural PCSK9 variants to generate enduring efficacy? That’s what our goal is with VERVE-102. At #EASCongress2025, we presented recent findings from our Heart-2 Phase 1b clinical…
Earlier this week we were honored to receive the SciSci Trailblazer award from @SciScientists. Since beginning our partnership in 2021, we’ve been inspired by their mission to ignite curiosity and empower the next generation of #STEM innovators. We are proud to give back and help…
Our team had a wonderful time at the #EASCongress2025 presenting recent highlights from our PCSK9 program and Verve’s vision of a one dose future to address #cardiovasculardisease. View the EAS presentation here: vervetx.com/sites/default/…
We’re looking forward to presenting at the #EASCongress2025 next week. For those on site, tune into our presentation which includes a discussion of the initial positive data from our Heart-2 trial of VERVE-102. You can also visit us at booth 7B! Learn more about the event here:…
Today is #DNAday, a day to celebrate the discovery of DNA's double helix structure and one of the most groundbreaking moments in science. This discovery paved the way for the field of genetics, and today, it's the foundation of the work we do every day at Verve. We’re utilizing a…
Verve was founded seven years ago with a vision of one treatment dose potentially leading to a lifetime reduction of low-density lipoprotein cholesterol (LDL-C) levels. Initial data from the Heart-2 Phase 1b clinical trial showed a strong dose-dependent response with total RNA…